Is the proposed 503B exclusion already a final determination?
Do not describe the proposal as final on the evidence retrieved. FDA’s April 30 announcement proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after finding no demonstrated clinical need in its evaluation. The announcement says comments would be considered before a final determination; this review did not establish a subsequent final disposition. (fda.gov)
Contract implication: Do not make a volume commitment dependent on a hoped-for regulatory outcome. Require counsel to assess the actual preparation and arrangement, including any subsequent FDA action and relevant litigation.
Is a shipping promise enough to establish continuity?
No—our recommended diligence standard is evidence of handling and recovery, not a delivery slogan. FDA reports complaints that some compounded GLP-1 products arrived warm or with inadequate cooling, and separately warns about fraudulent product labels and semaglutide salt forms. Those concerns warrant product-specific checks, not assumptions about every pharmacy. (fda.gov)
Quality action: Request the applicable storage specification, shipping qualification, excursion-assessment process, replacement policy and recall contacts. Do not accept a packaging photograph as proof that a shipment remained within its required conditions.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss